LubioScience expands Swiss access to cell and gene therapy solutions

Thursday, April 3, 2025 @ 12:00 am

LubioScience expands partnership with Amsbio, a global leader in life science reagents with a strong footprint in the cell and gene therapy, stem cell biology, 3D and organoid cell culture, glycobiology and the biospecimen field.

This collaboration ensures that Swiss researchers have greater access to Amsbio’s high-performance solutions, supporting advancements in regenerative medicine, stem cell research, and gene therapy.

For over 35 years, Amsbio has been a trusted provider of specialized reagents and custom services that are widely adopted in CGT workflows, from cell culture and cryopreservation to differentiation and therapeutic development. As part of this partnership, LubioScience now offers Swiss scientists streamlined access to Amsbio’s innovative products, including: CELLBANKER – A globally recognized cryopreservation medium that ensures high cell viability and recovery, critical for cell therapy applications. StemFit – A feeder-free culture medium optimized for the expansion and maintenance of pluripotent stem cells, essential for regenerative medicine research. iMatrix Laminin E8 Fragments – Recombinant laminin substrates that enhance cell adhesion and differentiation, widely used in stem cell and gene therapy studies.

Both LubioScience and Amsbio are part of Europa Biosite, a European distribution network dedicated to improving product accessibility and service excellence in life sciences. By combining LubioScience’s strong local expertise with Amsbio’s industry-leading CGT solutions, this partnership reinforces our commitment to supporting Swiss researchers from basic discovery to translational applications.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

ten23 health presents its fairstainability impact report

The report discusses ten23’s continued progress, with multiple international certifications and SBTi target validation, demonstrating its commitment to ambitious climate targets.
April 2, 2025

Pharvaris: EU orphan designation granted for treatment of bradykinin-mediated angioedema

April 1, 2025

SOPHiA GENETICS: 2 million patient cases analyzed, setting new milestone for data-driven medicine

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatch
March 18, 2025

Celonic leverages micro-bioreactor platform for perfusion-based bioprocessing

Celonic Group leverages Merck’s Breez micro-bioreactor technology to optimize bioprocessing efficiency and scalability. This technology integration supports Celonic’s efforts to enhance expertise in monoclonal antibody (mAb) development and manufacturing through advanced Next-Generation Technologies. Celonic’s streamlined production, enabled by Merck’s technology, sets new standards in red
March 12, 2025

Torqur: Interim Phase 2 clinical trial results for Actinic keratosis treatment

Full study results are expected in June 2025, but early results demonstrate strong potential; 60% of trial patients experienced full or partial lesion clearance.
March 10, 2025